<DOC>
	<DOCNO>NCT02228668</DOCNO>
	<brief_summary>The aim S-AVANT study collect additional data 8 10 year median follow patient previously include AVANT trial December 2004 June 2007 . Clinical data AVANT trial update . Neither additional examination administration treatment perform patient . 330 center 34 country participate AVANT trial ( Australia , Austria , Belgium , Brazil , Bulgaria , Canada , China/Hong-Kong , Czeck Republic , Finland , France , Germany , Greece , Hungary , Israël , Italy , Japan , Korean Republic , Mexico , Netherlands , New Zealand , Norway , Panama , Poland , Portugal , Russia Federation , Singapore , South Africa , Spain , Sweden , Switzerland , Taïwan , Thaïland , United Kingdom , U.S.A ) . The AVANT study aim demonstrate superiority bevacizumab combination FOLFOX-4 XELOX compare FOLFOX-4 , show prolongation DFS 3 year add bevacizumab chemotherapy resect stage III colon cancer . Adverse event consistent know safety profile bevacizumab . However , relapse death due disease progression observe bevacizumab arm . A prolonged follow-up necessary ass overall survival evaluate long-term result safety . Collection additional follow-up data start Q3 2014 . Clinical data collect 8-year median follow-up ( expect reach around Q2 2014 ) 10-year median follow-up ( expect reach around Q2 2016 ) . All analysis perform exploratory purpose . An analysis 8 year median follow-up final analysis 10 year median follow-up perform main population ( randomized patient AVANT trial include patient lose follow die ) .</brief_summary>
	<brief_title>Follow AVANT Study 8 10 Years ( Median Follow ) Patients With Colon Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>All patient randomize AVANT trial . Written opposition alive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>AVANT</keyword>
	<keyword>GERCOR</keyword>
	<keyword>Follow</keyword>
	<keyword>Colon cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Overall survival</keyword>
</DOC>